Related Experiment Videos
Growth factor and oncogene signalling pathways as targets for rational anticancer drug development
1Mayo Clinic and Foundation, Department of Pharmacology, Rochester, MN 55905.
Abstract:
There is a critical need for new targets, in addition to DNA, for anticancer drug development. A recently discovered target is the intracellular signalling pathways that mediate the actions of growth factors and oncogenes on cell proliferation. Two important pathways, the myo-inositol and protein tyrosine kinase signalling pathways are reviewed. Three classes of compounds that modulate myo-inositol signalling are discussed. These are: 1) the D-3-substituted-3-deoxy-myo-inositol analogues that act as antimetabolites of myo-inositol and show selective growth inhibition of some transformed cells; 2) the alkaloid staurosporine that acts as a potent inhibitor of protein kinase C and of platelet-derived growth factor (PDGF) receptor protein tyrosine kinase activity; 3) the ether lipid analogues that block growth factor signalling at several points by acting as inhibitors of protein kinase C, phosphoinositide specific phospholipase C and inositol(1,4,5)trisphosphate-induced Ca2+ release. It is suggested that inhibition of signalling pathways may explain the growth inhibitory effects of these compounds. Other potential signalling target sites for anticancer drug development are discussed.
Insights
New anticancer drug development strategies are exploring intracellular signaling pathways, not just DNA. Compounds targeting myo-inositol and protein tyrosine kinase pathways show promise in inhibiting cancer cell growth.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anticancer drug development urgently requires novel targets beyond DNA.
- Intracellular signaling pathways regulating cell proliferation are emerging as key targets.
- Focus on myo-inositol and protein tyrosine kinase pathways is crucial for understanding cancer growth.
Purpose of the Study:
- To review the roles of myo-inositol and protein tyrosine kinase signaling pathways in cancer.
- To discuss compounds that modulate these pathways for potential anticancer therapies.
- To explore new signaling target sites for future drug development.
Main Methods:
- Review of scientific literature on myo-inositol and protein tyrosine kinase signaling.
- Discussion of three classes of compounds: D-3-substituted-3-deoxy-myo-inositol analogues, staurosporine, and ether lipid analogues.
- Analysis of the mechanisms by which these compounds inhibit cancer cell proliferation.
Main Results:
- D-3-substituted-3-deoxy-myo-inositol analogues selectively inhibit transformed cell growth.
- Staurosporine potently inhibits protein kinase C and platelet-derived growth factor (PDGF) receptor tyrosine kinase.
- Ether lipid analogues inhibit multiple points in growth factor signaling, including protein kinase C and phospholipase C.
Conclusions:
- Inhibition of intracellular signaling pathways is a viable strategy for anticancer drug development.
- The discussed compounds demonstrate the potential of targeting myo-inositol and protein tyrosine kinase pathways.
- Further research into signaling pathways may uncover additional therapeutic targets for cancer treatment.